undamentalytics Newsletter
Sign in

Twist Bioscience Corp cash flow statement

In fiscal 2025, Twist Bioscience Corp's operations generated −$47.6m of cash; it spent $28.0m on capital projects, leaving free cash flow of −$75.6m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Cash from operations−51−66−88−142−112−124−142−64−48−53
Depreciation and amortisation5667101729312525
Stock-based pay231117378030516466
Capital spending741510271022852840
Free cash flow−58−70−103−152−139−226−170−69−76−93
Free cash flow after stock pay−60−73−114−169−176−306−201−120−140−160

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CSTL vs TWSTTWST vs VCYTFLGT vs TWST

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Twist Bioscience Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Twist Bioscience Corp.